Page 1

Optiscan Imaging Limited Appendix 4D Half - year report 1. Company details Name of entity : ABN : Reporting period : Previous period : Optiscan Imaging Limited 81 077 771 987 For the half - year ended 31 December 2020 For the half - year ended 31 December 2019 2. Results for announcement to the market ( OptiScan $ Revenues from ordinary activities up 60.4 % to 533,574 Loss from ordinary activities after tax attributable to the owners of Optiscan Imaging Limited down 37.5 % to ( 751,715 ) Loss for the half - year attributable to the owners of Optiscan Imaging Limited down 37.5 % to ( 751,715 ) Dividends There were no dividends paid or declared during the current financial period . Comments The loss for the consolidated entity after providing for income tax amounted to $ 751,715 ( 31 December 2019 : $ 1,203,481 ) . Financial performance During the 6 month period to 31 December 2020 ( H1FY21 ) , the consolidated entity generated ordinary revenue of $ 533,574 from sales , system rentals and the provision of services , compared to $ 332,684 in the previous corresponding period . The consolidated entity also recorded research and development incentive income for H1FY21 $ 289,640 , an increase of $ 7,662 from the previous corresponding period ( 2019 : $ 281,978 ) . Income of $ 249,569 from the BioMedTech Horizons program grant was also received . Total expenses for H1FY21 , excluding research and development and intellectual property expenses , were $ 1,172,470 , a decrease of $ 146,245 from the corresponding period ( 2019 : $ 1,318,715 ) . Research and development and intellectual property expenses were $ 665,839 , an increase of $ 162,592 from the previous corresponding period of $ 503,247 . Financial position The net assets increased by $ 8,744,553 to $ 10,292,876 at 31 December 2020 ( 30 June 2020 : $ 1,548,323 ) primarily due to the capital raising completed by the Company during the half year which raised $ 9,813,499 . The working capital position of the consolidated entity as at 31 December 2020 resulted in an excess of current assets over current liabilities of $ 10,053,550 ( 30 June 2020 : $ 1,264,761 ) . Net cash used in operating activities was $ 176,037 , a decrease of $ 834,510 compared to the corresponding period ( 2019 : operating cash outflows of $ 1,010,547 ) . The Company recorded an increase in receipts from research and development tax incentives and other government grants during the period amounting to $ 961,242 ( 2019 : $ 226,506 ) .